+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Preventive Immunotherapeutics in IBD: RFP

Crohn's & Colitis Foundation

Inflammatory bowel disease (IBD), particularly Crohn’s disease, remains characterized by high postoperative recurrence rates, with up to 70% of patients experiencing endoscopic recurrence within one year following surgical resection. While surgery removes diseased tissue, it does not address the underlying immune mechanisms that drive pathology, resulting in persistent mucosal inflammation and barrier dysfunction that triggers recurrent disease.

The postoperative period represents a unique biological window—before immune tolerance is lost and inflammation becomes re-established. This initiative supports immunotherapeutics-based academic research focused on preventing postoperative recurrence by training or reprogramming the immune system, rather than relying on chronic immune suppression.

Through this academic-focused RFP, the Crohn’s & Colitis Foundation seeks to advance translational, multi-year research on immune memory, antigen-specific responses, and immune regulation that may enable durable protection from recurrence and inform next-generation prophylactic immunotherapeutic strategies

Scope

Proposals should focus on immunology-based approaches relevant to secondary prevention of IBD recurrence following surgical resection, with an emphasis on shaping durable immune states rather than broadly suppressing immune activity.

Studies should be preclinical, using in vivo models of postoperative recurrence such as IL-10 null or HLA-B27 rodent models. Proposals can use organoid-based models by integrating patient-derived organoids with immune, stromal, microbial, and injury elements or through in vivo xenotransplantation in humanized (HIS) mouse models. Clinical studies will only be considered if postoperative patients are already enrolled and consented, and an IND (where applicable) is in place.

Areas of interest include, but are not limited to:

Antigen-specific immune tolerance induction
Immune-regulatory strategies
Cell therapies including but not restricted to in vivo and ex vivo expanded Tregs, stem cells, CAR-T

Proposals must be grounded in human IBD biology and clearly articulate how the proposed work advances immune-based prevention of postoperative recurrence.

Funding terms

$900,000 over three years ($300,000 per year, contingent upon achievement of annual milestones)

AI Based Application Success Predictor

🧠 1. Strong Focus on IBD (Non-Negotiable)

Projects must directly address:
- Inflammatory Bowel Disease (IBD)
  - Crohn’s disease
  - Ulcerative colitis

👉 Non-IBD GI research → low success probability

🎯 2. Clear Clinical & Patient Impact (Top Predictor)

Successful proposals:

Demonstrate:
- Improved patient outcomes
Focus on:
- Disease management
- Remission
- Quality of life

👉 Key question:
“Will this improve care for patients with IBD?”

🔄 3. Translational Research (Bench → Bedside) (Critical)

Strong preference for:
- Clinically relevant research
Includes:
- Biomarkers
- Therapeutic targets
- Clinical trials

👉 Pure basic science is less competitive unless linked to patient benefit

🔬 4. High Scientific Merit & Innovation

Must demonstrate:
- Strong hypothesis
- Novel approach
High success in:
- Microbiome research
- Immune mechanisms
- Precision medicine

👩‍🔬 5. Early-Career Investigator Development (Major Priority)

Many CCF programs target:
- Fellows and junior faculty

Evaluation includes:

Career trajectory
Potential for independence

👉 Strong mentorship is essential

🧪 6. Feasible, Well-Designed Study Plan

Must include:
- Clear aims
- Methodology
- Timeline

👉 Overly complex or underpowered studies are often rejected

🤝 7. Strong Mentorship & Institutional Support

Mentor should:
- Have IBD research expertise
Institution must provide:
- Clinical population
- Research infrastructure

👉 Mentorship quality strongly impacts success

🧬 8. Alignment with Priority Research Areas

Higher success rates in:

Microbiome & host interactions
Immune pathways
Fibrosis and complications
Pediatric IBD

👉 Topic alignment improves competitiveness

📊 9. Potential for Future Funding

CCF funding is often:
- Seed funding for NIH or major grants

👉 Projects that:

Generate preliminary data
Lead to publications
→ score higher

🌍 10. Patient-Centered Outcomes & Real-World Relevance

Increasing emphasis on:
- Patient-reported outcomes
- Real-world effectiveness
- Long-term disease management

👉 Patient-centered research is a growing differentiator

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

IBD-specific focus
Clinical/patient impact
Translational relevance

Moderate predictors:
4. Scientific merit
5. Early-career development
6. Feasibility

Supporting factors:
7. Mentorship
8. Topic alignment
9. Future funding potential

Specialties

Clinical Trials

Immunology

Eligibility Requirements

Applications are invited from academic research teams with complementary expertise in immunology and IBD. Each application must include:

One senior Principal Investigator (Professor, Head of Research, Associate Professor, or equivalent)
At least one junior Co-Principal Investigator (Instructor or Assistant Professor)

A multidisciplinary approach is encouraged, including integration of patient-derived data to inform and strengthen the proposed immune-based therapeutic strategy. U.S. and international investigators are eligible to apply.

For-profit biopharmaceutical enterprises, live microbiome therapeutics, and broad immunosuppressive strategies are not eligible.

Sponsor Details

Sponsor Institute/Organizations: Crohn's & Colitis Foundation

Sponsor Type: Corporate/Non-Profit

Address: 733 THIRD AVENUE, SUITE 510, NEW YORK, NY 10017

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity